List of antidepressants
This is a complete list of clinically approved prescription antidepressants throughout the world, as well as clinically approved prescription drugs used to augment antidepressants or mood stabilizers, by pharmacological and/or structural classification. Chemical/generic names are listed first, with brand names in parentheses. All drugs listed are approved specifically for major depressive disorder unless noted otherwise.
Selective serotonin reuptake inhibitors (SSRIs)
- Citalopram (Celexa, Cipramil)
- Escitalopram (Lexapro, Cipralex)
- Fluoxetine (Prozac, Sarafem)
- Fluvoxamine (Luvox, Faverin)
- Paroxetine (Paxil, Seroxat)
- Sertraline (Zoloft, Lustral)
Discontinued/withdrawn
- Indalpine (Upstene)
- Zimelidine (Normud, Zelmid)
Serotonin–norepinephrine reuptake inhibitors (SNRIs)
- Desvenlafaxine (Pristiq)
- Duloxetine (Cymbalta)
- Levomilnacipran (Fetzima)
- Milnacipran (Ixel, Savella, Milnaneurax)
- Venlafaxine (Effexor, Trevilor)
Serotonin modulators and stimulators (SMSs)
- Vilazodone (Viibryd)
- Vortioxetine (Trintellix, Brintellix)
Serotonin antagonist and reuptake inhibitors (SARIs)
- Nefazodone (Dutonin, Nefadar, Serzone) – withdrawn/discontinued in most countries
- Trazodone (Desyrel)
Discontinued/withdrawn
- Etoperidone (Axiomin, Etonin)
Norepinephrine reuptake inhibitors (NRIs)
- Reboxetine (Edronax)
- Teniloxazine (Lucelan, Metatone) – also a 5-HT2A receptor antagonist
- Viloxazine (Vivalan) – also a 5-HT2B receptor antagonist and 5-HT2C receptor agonist
Off-label only
- Atomoxetine (Strattera)[1][2][3][4]
Norepinephrine–dopamine reuptake inhibitors (NDRIs)
- Bupropion (Wellbutrin, Elontril) – also a non-competitive antagonist of nicotinic acetylcholine receptors[5]
Off-label only
- Amphetamines (e.g., Adderall, Dexedrine, Vyvanse) – actually norepinephrine–dopamine releasing agents (NDRAs)[6][4]
- Methylphenidate (Ritalin)[7][8]
- Modafinil (Provigil) – actually a selective dopamine reuptake inhibitor plus other actions[9][10][11][12]
Discontinued/withdrawn
- Amineptine (Survector, Maneon)
- Nomifensine (Merital, Alival)
Tricyclic antidepressants (TCAs)
- Amitriptyline (Elavil, Endep)
- Amitriptylinoxide (Amioxid, Ambivalon, Equilibrin)
- Clomipramine (Anafranil)
- Desipramine (Norpramin, Pertofrane)
- Dibenzepin (Noveril, Victoril)
- Dimetacrine (Istonil)
- Dosulepin (Prothiaden)
- Doxepin (Adapin, Sinequan)
- Imipramine (Tofranil)
- Lofepramine (Lomont, Gamanil)
- Melitracen (Dixeran, Melixeran, Trausabun)
- Nitroxazepine (Sintamil)
- Nortriptyline (Pamelor, Aventyl)
- Noxiptiline (Agedal, Elronon, Nogedal)
- Opipramol (Insidon)
- Pipofezine (Azafen/Azaphen)
- Protriptyline (Vivactil)
- Trimipramine (Surmontil)
Amineptine (Survector, Maneon) and tianeptine (Stablon, Coaxil) are technically TCAs but are atypical, and are grouped elsewhere.
Discontinued/withdrawn
- Butriptyline (Evadyne)
- Demexiptiline (Deparon, Tinoran)
- Fluacizine (Phtorazisin)
- Imipraminoxide (Imiprex, Elepsin)
- Iprindole (Prondol, Galatur, Tetran)
- Metapramine (Timaxel)
- Propizepine (Depressin, Vagran)
- Quinupramine (Kinupril, Kevopril)
- Tiazesim (Altinil) – actually not a TCA but a tricyclic-like antidepressant
- Tofenacin (Elamol, Tofacine) – actually not a TCA but a tricyclic-like antidepressant
Tetracyclic antidepressants (TeCAs)
- Amoxapine (Asendin)
- Maprotiline (Ludiomil)
- Mianserin (Tolvon)
- Mirtazapine (Remeron)
- Setiptiline (Tecipul)
Mianserin, mirtazapine, and setiptiline are also sometimes described as noradrenergic and specific serotonergic antidepressants (NaSSAs).
Monoamine oxidase inhibitors (MAOIs)
Non-selective
- Isocarboxazid (Marplan)
- Phenelzine (Nardil)
- Tranylcypromine (Parnate)
Discontinued/withdrawn
- Benmoxin (Neuralex)
- Iproclozide (Sursum)
- Iproniazid (Marsilid)
- Mebanazine (Actomol)
- Nialamide (Niamid)
- Octamoxin (Ximaol)
- Pheniprazine (Catron)
- Phenoxypropazine (Drazine)
- Pivhydrazine (Tersavid)
- Safrazine (Safra)
Selective for MAO-B
- Selegiline (Eldepryl, Zelapar, Emsam)
Selective for MAO-A
- Metralindole (Inkazan)
- Moclobemide (Aurorix, Manerix)
- Pirlindole (Pirazidol)
These drugs are sometimes described as reversible inhibitors of MAO-A (RIMAs).
Discontinued/withdrawn
- Eprobemide (Befol)
- Minaprine (Brantur, Cantor)
- Toloxatone (Humoryl)
Non-selective
- Bifemelane (Alnert, Celeport) – RIMA, irreversible inhibitor of MAO-B, and weak NRI
Atypical antipsychotics
- Amisulpride (Solian) – approved in low doses as a monotherapy for persistent depression
- Lumateperone (Caplyta) – approved as a monotherapy for bipolar depression
- Lurasidone (Latuda) – approved as a monotherapy for bipolar depression
- Quetiapine (Seroquel) – approved as a monotherapy for bipolar depression
Others
Marketed
- Agomelatine (Valdoxan) – 5-HT2C receptor antagonist and MT1 and MT2 receptor agonist
- Brexanolone (allopregnanolone; Zulresso) – GABAA receptor positive allosteric modulator – approved for postpartum depression
- Bupropion/dextromethorphan (Auvelity) – non-competitive NMDA receptor antagonist, σ1 receptor agonist, serotonin–norepinephrine reuptake inhibitor, norepinephrine–dopamine reuptake inhibitor, other actions
- Esketamine (Spravato) – non-competitive NMDA receptor antagonist, other actions[13]
- Tianeptine (Stablon, Coaxil, Tianeurax) – weak and atypical μ-opioid receptor agonist, other actions
Off-label only
- Ketamine (Ketalar) – non-competitive NMDA receptor antagonist[14]
Discontinued/withdrawn
- α-Methyltryptamine [αMT] (Indopan) – non-selective serotonin receptor agonist, serotonin–norepinephrine–dopamine releasing agent (SNDRA), and weak RIMA
- Etryptamine [α-Ethyltryptamine (αET)] (Monase) – non-selective serotonin receptor agonist, SNDRA, and weak RIMA
- Indeloxazine (Elen, Noin) – serotonin releasing agent (SRA), NRI, and NMDA receptor antagonist
- Medifoxamine (Clédial, Gerdaxyl) – weak serotonin–dopamine reuptake inhibitor (SDRI) and 5-HT2A and 5-HT2C receptor antagonist
- Oxaflozane (Conflictan) – 5-HT1A, 5-HT2A, and 5-HT2C receptor agonist
- Pivagabine (Tonerg) – unknown/unclear mechanism of action
Over-the-counter
The following antidepressants are available both with a prescription and over-the-counter:
- Ademetionine [S-Adenosyl-L-methionine (SAMe)] (Heptral, Transmetil, Samyl) – cofactor in monoamine neurotransmitter biosynthesis
- Hypericum perforatum [St. John's Wort (SJW)] (Jarsin, Kira, Movina) – TRPC6 activator, and various other actions
- Oxitriptan [5-Hydroxytryptophan (5-HTP)] (Cincofarm, Levothym, Triptum) – precursor in serotonin biosynthesis
- Tryptophan (Tryptan, Optimax, Aminomine) – precursor in serotonin biosynthesis
Adjunctive treatments
Atypical antipsychotics
- Aripiprazole (Abilify) – approved as an adjunct to antidepressant for major depression
- Brexpiprazole (Rexulti) – approved as an adjunct to antidepressant for major depression
- Lumateperone (Caplyta) – approved as an adjunct to mood stabilizer for bipolar depression
- Lurasidone (Latuda) – approved as an adjunct to mood stabilizer for bipolar depression
- Olanzapine (Zyprexa) – approved as an adjunct to antidepressant for major depression
- Quetiapine (Seroquel) – approved as an adjunct to antidepressant or mood stabilizer for major depression and bipolar depression
Off-label only
- Risperidone (Risperdal)
Off-label only
- Trifluoperazine (Stelazine)[15]
Off-label only
- Buspirone (Buspar) – 5-HT1A receptor partial agonist
- Lithium (Eskalith, Lithobid) – mood stabilizer (mechanism of action unknown/unclear)
- Thyroxine (T4) – thyroid hormone (thyroid hormone receptor agonist)
- Triiodothyronine (T3) – thyroid hormone (thyroid hormone receptor agonist)
Combination products
- Amitriptyline/chlordiazepoxide (Limbitrol) – TCA and benzodiazepine combination
- Amitriptyline/perphenazine (Etafron) – TCA and typical antipsychotic combination
- Flupentixol/melitracen (Deanxit) – TCA and typical antipsychotic combination
- Olanzapine/fluoxetine (Symbyax) – SSRI and atypical antipsychotic combination – approved as a monotherapy for bipolar depression and treatment-resistant depression
- Tranylcypromine/trifluoperazine (Parstelin, Parmodalin, Jatrosom N, Stelapar) – MAOI and typical antipsychotic combination
References
- Fedder D, Patel H, Saadabadi A (2021). "Atomoxetine". PMID 29630286.
{{cite journal}}: Cite journal requires|journal=(help) - Dell'Osso B, Palazzo MC, Oldani L, Altamura AC (December 2011). "The noradrenergic action in antidepressant treatments: pharmacological and clinical aspects". CNS Neurosci Ther. 17 (6): 723–32. doi:10.1111/j.1755-5949.2010.00217.x. PMC 6493872. PMID 21155988.
- Fleurence R, Williamson R, Jing Y, Kim E, Tran QV, Pikalov AS, Thase ME (2009). "A systematic review of augmentation strategies for patients with major depressive disorder". Psychopharmacol Bull. 42 (3): 57–90. PMID 19752841.
- Corp SA, Gitlin MJ, Altshuler LL (September 2014). "A review of the use of stimulants and stimulant alternatives in treating bipolar depression and major depressive disorder". J Clin Psychiatry. 75 (9): 1010–8. doi:10.4088/JCP.13r08851. PMID 25295426.
- Arias HR, Santamaría A, Ali SF (2009). "Pharmacological and neurotoxicological actions mediated by bupropion and diethylpropion". Int. Rev. Neurobiol. International Review of Neurobiology. 88: 223–55. doi:10.1016/S0074-7742(09)88009-4. ISBN 9780123745040. PMID 19897080.
- Dale E, Bang-Andersen B, Sánchez C (2015). "Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs". Biochem. Pharmacol. 95 (2): 81–97. doi:10.1016/j.bcp.2015.03.011. PMID 25813654.
- Challman TD, Lipsky JJ (2000). "Methylphenidate: its pharmacology and uses". Mayo Clin. Proc. 75 (7): 711–21. doi:10.4065/75.7.711. PMID 10907387.
- Prommer E (2012). "Methylphenidate: established and expanding roles in symptom management". Am J Hosp Palliat Care. 29 (6): 483–90. doi:10.1177/1049909111427029. PMID 22144657.
- Urban AE, Cubała WJ (February 2020). "The role of eugeroics in the treatment of affective disorders". Psychiatr Pol. 54 (1): 21–33. doi:10.12740/PP/OnlineFirst/90687. PMID 32447354.
- Kleeblatt J, Betzler F, Kilarski LL, Bschor T, Köhler S (May 2017). "Efficacy of off-label augmentation in unipolar depression: A systematic review of the evidence". Eur Neuropsychopharmacol. 27 (5): 423–441. doi:10.1016/j.euroneuro.2017.03.003. PMID 28318897. S2CID 3740987.
- Nunez NA, Singh B, Romo-Nava F, Joseph B, Veldic M, Cuellar-Barboza A, Cabello Arreola A, Vande Voort JL, Croarkin P, Moore KM, Biernacka J, McElroy SL, Frye MA (March 2020). "Efficacy and tolerability of adjunctive modafinil/armodafinil in bipolar depression: A meta-analysis of randomized controlled trials". Bipolar Disord. 22 (2): 109–120. doi:10.1111/bdi.12859. PMID 31643130.
- Szmulewicz AG, Angriman F, Samamé C, Ferraris A, Vigo D, Strejilevich SA (June 2017). "Dopaminergic agents in the treatment of bipolar depression: a systematic review and meta-analysis". Acta Psychiatr Scand. 135 (6): 527–538. doi:10.1111/acps.12712. PMID 28256707. S2CID 3712257.
- "SPRAVATO™ (esketamine) nasal spray FDA label" (PDF). Food and Drug Administration. 5 March 2019. Retrieved 6 March 2019.
- Zhang MW, Harris KM, Ho RC (2016). "Is off-label repeat prescription of ketamine as a rapid antidepressant safe? Controversies, ethical concerns, and legal implications". BMC Med Ethics. 17: 4. doi:10.1186/s12910-016-0087-3. PMC 4714497. PMID 26768892.
- Thase ME (2016). "Adverse Effects of Second-Generation Antipsychotics as Adjuncts to Antidepressants: Are the Risks Worth the Benefits?". Psychiatr. Clin. North Am. 39 (3): 477–86. doi:10.1016/j.psc.2016.04.008. PMID 27514300.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.